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Background: Assessment of muscle wasting in COPD is relevant as it is independently associ-
ated with metabolic and functional consequences and even survival. Muscle wasting can be ap-
proached by assessing fat free mass (FFM), but it is already demonstrated that FFM measured
by bio-electrical impedance analysis (BIA) underestimates FFM measured by dual energy X-ray
absorptiometry (FFMDExA) in a relatively small COPD group.
Objective: To evaluated critical points for defining muscle wasting in a large cohort of
moderate to severe COPD patients and with DEXA scan as reference.
Design: FFM by BIA was compared with FFMDExA in 1087 COPD patients (641_, FEV1:
44.8 17.5%pred). In a subgroup (nZ 422), FFMDExA was predicted by multivariate analysis
and a new formula to calculate FFM by BIA was developed. The new formula was compared
with FFMDExA in the remaining subgroup (nZ 665). Muscle wasting was defined according to
the cut-offs of Schols et al. (FFM index (FFMI)<16 kg/m2 for men, 15 kg/m2 for women), Vestbo
et al. (FFMI< 17.1 kg/m2 for men, 14.6 kg/m2 for women), and Coin et al. (FFMI< 17.8 kg/m2
for men, 14.6 kg/m2 for women).
Results: There was an underestimation of FFM by BIA when compared to FFMDExA by the Bland
Altman. Comparing the new formula with FFMDExA, the mean underestimation almost disap-
peared but the variation remained. The proportion of muscle wasting was largely dependent
on the used cut-offs, especially in men.
Conclusion: The results of the present study emphasize the importance to accurately bare in
mind the technique and cut-offs to establish muscle wasting before implementing it in the
clinical practice.
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Besides the respiratory disorder, chronic obstructive
pulmonary disease (COPD) is nowadays generally accepted
as a systemic disease.1 Decreased skeletal muscle mass is
one of the most investigated extra-pulmonary features in
COPD. Indeed, an abnormal low muscle mass is present in
about 40% of the patients with moderate to severe COPD
entering pulmonary rehabilitation.2 A comparable propor-
tion of muscle wasting of about 30% was found in a large
group of COPD outpatients with GOLD stages 2 and 3,
independent of patients’ body weight.3
Muscle wasting is negatively associated with exercise
capacity4 and quality of life5 in COPD. Moreover, mortality
rate is higher in COPD patients with muscle wasting than in
those patients with preserved muscle mass, independent
of the body weight.6 Therefore, an accurate diagnosis of
muscle wasting in COPD is clinically relevant. Indeed,
clinical experience indicates that assessment of body
composition is increasingly embedded in the clinical
management of patients with COPD. Nevertheless, the
prevalence of muscle wasting is largely dependent on the
used technique. The dual energy X-ray absorptiometry
(DEXA) scan has been shown to be accurate for the
measurement for the lean body mass in healthy subjects7
and in patients with COPD.8,9 However, this technique is
rather expensive and therefore not easy to use in clinical
routine. Single-frequency bio-electrical impedance anal-
ysis (BIA) is also recognized as a reliable and useful tool to
assess fat free mass (FFM, a marker for skeletal muscle
mass) in clinical practice.10 However, the FFM derived
from this technique is dependent on the formula used.
Various general and patient specific formulas are circu-
lating, and some of them are age-dependent while others
are not. Research has shown a standard underestimation of
the FFM assessed by BIA when compared to the FFM
assessed by DEXA scan in patients with COPD.11,12 So, the
current COPD specific formula to estimate FFM using the
BIA does not seem to be accurate enough when compared
with DEXA measures. Moreover, the formula has been
based on a group of only 117 COPD patients in total.11
Therefore, there seems to be a clear rationale to evaluate
the formula to estimate FFM by BIA in a large cohort of
COPD patients. Finally, the prevalence of muscle wasting is
dependent on the used cut offs. To date, various COPD
specific cut offs are circulating,3 but a proof of principle is
warranted.
In the present study, FFM is measured by the BIA and
compared with the FFM measured by DEXA (FFMDExA) in
a large cohort of clinically stable patients with moderate to
severe COPD entering pulmonary rehabilitation. The DEXA
scan is used as the reference method for assessing skeletal
muscle mass. Using multivariate stepwise regression anal-
ysis, FFMDExA is predicted in a subgroup of the patients by
using the impedance received from the BIA. The new
formula obtained from the regression equation was evalu-
ated in the remaining group and in various age groups. In
addition, the proportion of muscle wasting was determined
in our sample using the different techniques and using
various cut-offs widely used to define muscle wasting in
COPD3 and healthy elderly.7Subjects and methods
Study population
Data were retrospectively collected in 1087 patients with
COPD (641_) during the screening for a pulmonary reha-
bilitation program at the Center of expertise for chronic
organ failure (Ciro) in Horn, the Netherlands between
January 2005 and June 2008.13 Screening takes always
place before entering the pulmonary rehabilitation. Lung
function parameters were collected using standardized
spirometry (Masterlab, Viasys, Germany). Diffusion
capacity of carbon monoxide was assessed by single-breath
method (Masterlab, Jaeger, Germany). Current lung
related medication use was as follows: fluticason (41.8%),
tiotropium (41.4%), acetyl cysteine (29,8%), combivent
(formoterol and budesonide, 29.6%), salbutamol (23.9%),
formoterol (21.8%), ipratropium (21.6%), dimethylxantine
(21.8%) and oral corticosteroids as maintenance dose
(19.6%). All patients were clinically stable and those with
clinically diagnosed edema were excluded from the study.
Body composition
Body height was measured to the nearest 0.1 cm. Body
composition was assessed by using two different techniques
in the post-absorptive state and within 2 days. For the BIA
analysis (Bodystat), body weight was assessed by using an
electronic beam scale with digital readout to the nearest
0.1 kg after emptying the bladder and with the subjects
standing barefoot and wearing light indoor clothing. Whole
body impedance (expressed in U) was measured in each
subject by lying on the bed and with separated legs. For the
calculation of the FFM, the patient and sex-specific formula
of Steiner et al. was used11: FFMmenZ 8.383þ 0.465
height2/impedanceþ 0.213weight, FFMwomenZ 7.610þ
0.474 height2/impedanceþ 0.184weight. The FFM
derived from the BIA and calculated by Steiner’s formula
will be abbreviated as FFMSteiner. Fat free mass index (FFMI)
was calculated as FFM divided by height2. A total body scan
was performed by DEXA using a Lunar Prodigy system (GE
Healthcare, Madison, WI, USA). For this purpose, subjects
lied in supine position on a scan table for approximately
15 minutes while the DEXA scanner performed multiple fast
speed transverse scans from head to toes. From the total
body scan, FFM was assessed by summing up lean mass and
bone mineral content. FFM derived from the DEXA will be
abbreviated as FFMDexa, and is used as reference values.
Statistical analyses
Data were normally distributed and reported as mean
 standard deviation (SD). Sex-differences were tested
using an unpaired Student’s t-test. The group was randomly
split into two groups with comparable general character-
istics (Table 1). In the first group of 422 subjects, stepwise
multiple regression analysis with FFMDExA as dependent
variable and age, sex, height, weight and height2/(imped-
ance from the BIA) as independent variables is performed.
From this, a new regression formula was created (FFMForm).
Table 1 Baseline characteristics of the two subgroups of
the total study population.
First group Second group
Subjects, n 422 665
Male, % 59.8% 59.1%
Age, y 63.5 9.8 63.1 9.6
Height, m 167.8 8.7 167.8 8.9
Weight, kg 69.4 15.1 69.0 15.2
BMI, kg/m2 24.6 4.6 24.4 4.8
BMC, g 2448.7 978.9 2453.7 747.4
FEV1, %pred 42.1 16.1 46.3 18.9
FEV1/FVC 42.4 12.6 39.4 12.7
DLCO, %pred 53.8 38.4 51.0 18.9
Data are mean SD.
Abbreviations: BMC: bone mineral content; FEV1: forced expi-
ratory volume expressed in 1 s; FEV1/FVC: Tiffeneau index;
DLCO: diffusing capacity for carbon monoxide. No significances.
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the whole group and between FFMForm and FFMDExA in the
second group (nZ 665) was tested by calculating Pearson’s
correlation coefficient. The limits of agreement of the
FFMSteiner and FFMForm with the FFMDExA were determined by
plotting the mean intermethod measurement differ-
ence 2 standard deviations (SD) as described by Bland and
Altman.14 Age dependency of the FFMDExA was tested by
analysis of variance (ANOVA) test and post hoc LSD test. To
test differences between FFMDExA and FFMForm and the
other formulas by Dey et al.,15 Deurenberg et al.,16 Steiner
et al.11 and Segal et al.,17 the paired Student’s t-test was
used. Muscle wasting was defined according to the cut-offs
of Schols et al. (FFMI< 16 kg/m2 for men, 15 kg/m2 for
women), Vestbo et al. (FFMI< 17.1 kg/m2 for men, 14.6 kg/
m2 for women)3 and Coin et al. (10th percentile in the age
range 60e69: FFMI< 17.8 kg/m2 for men, 14.6 kg/m2 for
women).7 The prevalence of muscle wasting between the
different techniques was tested by using the chi2-test.
Analyses were performed using Statistical Package for
the Social Sciences (SPSS) version 15.01 for Windows.
A p-value< 0.05 was considered statistically significant.Table 2 Baseline characteristics of the study group.
Men Women
Subjects, n 641 446
Age, y 65.4 9.4 60.1 9.3**
Height, m 172.5 7.0 161.0 6.4**
Weight, kg 73.9 14.5 62.4 13.5**
BMI, kg/m2 24.8 4.4 24.1 5.1*
BMC, g 2713.5 693.5 2075.5 898.9**
FEV1, %pred 44.0 16.8 45.7 13.4
FEV1/FVC 39.6 12.1 41.8 13.4
DLCO, %pred 52.8 20.4 49.1 18.4
Data are mean SD.
Abbreviations: BMC: bone mineral content; FEV1: forced expi-
ratory volume expressed in 1 s; FEV1/FVC: Tiffeneau index;
DLCO: diffusing capacity for carbon monoxide. Significantly
different compared to men: *p< 0.05, **p< 0.01.Results
Characteristics of the patients are shown in Table 2. The
patients were characterized by moderate to severe COPD.
The women were younger than the men and they had lower
weight, BMI and bone mineral content, but the same degree
of lung function impairment.
The coefficient of determination between mean
FFMSteiner and FFMDExA was 0.88 and comparable between
men and women (R2Z 0.80 vs. 0.74, respectively; both
p< 0.01, Fig. 1A). Limits of agreement between theFigure 1 Correlation between FFMSteiner and FFMDExA (A) and
intermethod agreement of FFM measurements for DEXA and
BIA (B) in male (white dots) and female (black triangles)
patients with COPD. Mean differences (solid line) and limits of
agreement (2 SD, dashed line) are shown for the whole
population.
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Fig. 1B. Particularly in men, FFMSteiner underestimated FFM
when compared with FFMDExA (mean difference FFM(DExAe
Steiner) in men: 4.1 kg (limits of agreement 2.6 to 10.8 kg),
in women: 1.4 kg (limits of agreement 5.5 to 8.3 kg)).
FFMDExA was significantly correlated with age, gender,
height, weight and height2/impedance (data not shown, all
p< 0.01). Subsequently, a stepwise multiple regression
analysis with FFMDExA as the dependent variable and age,
gender, height, weight and height2/impedance as the
independent variable was performed in the first subgroup
of 422 subjects. The significant covariates gender, height,
weight and height2/impedance showed a prediction of 90%
(Table 3). From this, a sex-specific formula to calculate FFM
by the impedance in our COPD population was created:
FFMFormZ11.81þ 0.245weightþ 0.298 height2/impe-
danceþ 0.148 heightþ 5.284 sex (1 for men, 0 for
women). The coefficient of determination between mean
FFMForm and FFMDExA in the second group of 665 subjects was
0.91 and comparable betweenmen andwomen (R2Z 0.82 vs.
0.77, respectively; both p< 0.01, Fig. 2A). Limits of agree-
ment between FFMForm and FFMDExA are shown in Fig. 2B
(mean difference FFM(DExAeForm) in men: 0.57 kg (limits of
agreement 5.6 to 6.7 kg), in women: 0.68 kg (limits of
agreement 4.2 to 5.5 kg)). Exploring the correlation of the
FFMI between the different techniques, led to R2Z 0.76
between the FFMIDExA and FFMISteiner and R
2Z 0.93 between
the FFMIDExA and FFMIForm.
Fig. 3 presented the age dependency of FFMDExA,
FFMForm and other formulas used for patients with COPD
(FFMSteiner,
11 Segal et al.17) and healthy elderly (Deurenberg
et al.,16 Dey et al.15). In men (Fig. 3A), FFMDExA decreased
with increasing age (p< 0.01), while in women (Fig. 3B),
FFMDExA was not age-dependent. As expected, the new
formula was closely linked to the FFMDExA, as did the
formula by Dey. The formulas by Deurenberg and Steiner
significantly underestimated the FFM when compared to
the FFMDExA (p< 0.01) while the formula by Segal signifi-
cantly overestimated the FFMDExA (p< 0.01).Table 3 Multivariate stepwise regression with FFM
derived from the DEXA scan as dependent variable.
Independent variable R2 B P-value
Model 1 0.80
Height2/impedance 0.79 0.00
Model 2 0.84
Height2/impedance 0.59 0.00
Weight 0.19 0.00
Model 3 0.89
Height2/impedance 0.37 0.00
Weight 0.24 0.00
Sex 5.94 0.00
Model 4 0.90
Height2/impedance 0.30 0.00
Weight 0.25 0.00
Sex 5.28 0.00
Height 0.15 0.00
Newly formed formula: 11.81þ 0.245weightþ 0.298
height2/impedanceþ 0.148heightþ 5.284sex (sexZ 1 for
men, 0 for women).
Figure 2 Correlation between FFMForm and FFMDExA (A) and
intermethod agreement of FFM measurements for DEXA and
the calculated FFM (B) in a subgroup of male (white dots)
and female (black triangles) patients with COPD (nZ 665).
Mean differences (solid line) and limits of agreement (2 SD,
dashed line) are shown for the whole subgroup.In Fig. 4, the percentage of patients with muscle wasting
calculated by the cut offs of Schols et al.2 (A), Vestbo et al.3
(B) and Coin et al.7 (C) is shown. FFMI is derived from DEXA
scan and BIA after which FFM is calculated by the formula of
Steiner et al. and the new formula. In both in men and in
women, the proportion of muscle wasting was higher using
the FFMSteiner vs. the FFMDExA and FFMForm (both p< 0.01).
Comparing the proportion muscle wasting derived from the
FFMDExA with the FFMForm, the difference was statistically
Figure 3 FFM by DEXA scan and various formulas in male (A)
and female (B) COPD patients in different age categories.
Figure 4 Percentage of muscle wasting in male and female
patients with COPD by using the formula by Steiner et al. (black
bars), the FFM derived from the DEXA (grey bars) and with the
FFM calculated by the new formula (white bars). Muscle
wasting was defined according to the cut-offs of Schols et al.
(A, FFMI< 16 kg/m2 for men and 15 kg/m2 for women), Vestbo
et al. (B, FFMI< 17.1 kg/m2 for men and 14.6 kg/m2 for
women) (3) and Coin et al. (C, 10th percentile in the age range
60e69: 17.8 kg/m2 for men and 14.6 kg/m2 for women).
Significant different from FFMDExA: **P< 0.01.
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proportion muscle wasting was only 3.9% for the criteria of
Schols, 5.3% for the 10th percentile of Vestbo et al. and 3.4%
for the 10th percentile of Coin et al.
Discussion
The present study evaluated critical points in the assess-
ment of muscle wasting in a large group of moderate to
severe clinically stable patients with COPD. An underesti-
mation of the FFM measured by BIA and calculated by
Steiner’s formula is found when compared to the FFM
measured by DEXA. As this underestimation is already
previously shown,11 the authors approached to create a new
formula to calculate FFM by BIA by using the stepwise
multivariate regression. From this, a new COPD specific
formula was formed. The proportion of muscle wasting is
largely dependent on the used cut-offs, especially in men.
The findings of the present study emphasize the importance
to accurately bare in mind these criteria to establish muscle
wasting before implementing it in the clinical practice.
It has previously been shown that muscle wasting is
associated with metabolic18 and functional conse-
quences.19 Assessment of body mass index alone for
screening on body composition in patients with COPD seems
not accurate as there is a subgroup of patients with normal
BMI and muscle wasting.2 Therefore, defining muscle
wasting in the screening and the treatment of COPD
patients is clinically relevant. The present study shows that
the accuracy of this definition depends on various factors
like the technique used to measure FFM and the cut-offs onwhich muscle wasting is based. Both factors will be dis-
cussed in the following section.
Various studies evaluated the proportion of muscle mass
in patients with COPD by using different techniques and
with the DEXA scan as the reference method.11,12 In both
studies, there is great discrepancy of the limits of agree-
ment when the BIA and the anthropometric methods were
compared with the DEXA scan. Conclusive, the proportion
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the technique used. Even, besides intra-technical differ-
ences (various soft wares for DEXA scan, different BIA
devices), inter-technical differences are even greater. In
the study by Steiner et al.,11 the prevalence of muscle
wasting was 36 and 42% in men and 72 and 59% in women
when respectively the DEXA and BIA was used. In the more
recent study by Lerario et al.,12 the changes between the
DEXA scan and BIA were smaller, respectively 25 and 28%. In
both studies, the cut-offs of Schols et al. were used to
define muscle wasting.2 Moreover, the proportion of muscle
wasting was higher in the study by Steiner et al.11 compared
to the study by Lerario et al.,12 likely partly because the
patients included in the study by Steiner et al. had more
severe COPD. Both studies concluded that BIA under-
estimated FFM when compared with DEXA. In the present
study, the proportion of muscle wasting according to the
cut-offs of Schols et al. was about 15 and 37% for men and
about 45 and 59% for women for respectively DEXA and BIA.
The discrepancy between methods may have great impact
as nutritional supplements are often prescribed in clinical
research,20,21 but also in patient’s health care.22 In this
view, the new formula in the present study is proficient to
minimize the discrepancy of the FFM, and particularly the
FFMI that existed between the DEXA and the BIA method.
However, as relatively great limits of agreements remain
with the new formula, the DEXA device still is more
profound to screen for muscle wasting, as confirmed in
a recent published paper.9 If the BIA method is only at
hand, the new formula may give a better approach to
estimate skeletal muscle mass than previous COPD specific
formulas.
Recently, three studies summarized the prevalence of
muscle wasting in cohorts of COPD outpatients3,23,24
(Table 4). In all these studies, BIA was used to calculate
FFM, and the prevalence of muscle wasting was defined by
the cut-offs of Schols et al. The formulas of Segal et al.3,23,24
and Steiner et al.3,23,24 were used to calculated FFM. The
proportion of muscle wasting in the present study is higher
when compared to the other studies. This can at least partly
be explained by the fact that we studied complex COPD
patients admitted for pulmonary rehabilitation. Until now,
there is no study that appraises muscle wasting by using the
DEXA scan in a large group of COPD patients.
The findings of the present study emphasis the impor-
tance of the cut-offs for defining muscle wasting. The cut-
offs of Schols et al. (FFMI< 16 kg/m2 for men and 15 kg/m2Table 4 Proportion of muscle wasting in various studies.
% of patients
with muscle wasting
Formula Men Women References
Vermeeren et al. Steiner 20 40 [20]
Vestbo et al. Segal 7 36 [3]
Steuten et al. Steiner 20 29 [4]
Present studya Steiner 37 59
In all studies, COPD outpatients were included, BIA was used to
estimate fat free mass, and the prevalence of muscle wasting
was defined by the criteria of Schols et al.2
a The original BIA calculation was used.for women) are based on the percentage of ideal body
weight,2 while the cut-offs of Vestbo et al.3 and of Coin
et al.7 are based on the 10th percentile of a large cohort of
healthy subjects in respectively Copenhagen (age range
20e93) and various parts in Italy (age range 60e69). The
cut-off for women is similar for the Copenhagen and Italy
cohort (FFMI< 14.6 kg/m2), and only slightly lower than
the cut-off of Schols et al. A larger discrepancy exists in the
cut-offs for men. The 10th percentile of the FFMI in the
Copenhagen and Italy cohort for men is respectively
17.1 kg/m2 and 17.8 kg/m2. The cut-off of Vestbo et al.
(17.1 kg/m2),3 is positioned between the cut-off of Schols
et al. (16 kg/m2),2 and Coin et al. (17.8 kg/m2).7 Together
with the fact that the proportion of muscle wasting based
on the cut-off of Vestbo et al. in men move toward the
proportion in women (see Fig. 4), the authors conclude that
the cut-offs of Vestbo et al. approach most optimal the cut-
offs for defining muscle wasting. Based on these cut offs,
the prevalence of muscle wasting in the present cohort of
moderate to severe patients with COPD admitted for
pulmonary rehabilitation is about 30% for both men and
women. Nevertheless, the present authors believe that
future epidemiologic research has to further evaluate the
criteria for diagnosing muscle wasting in chronically ill
patients.
To further evaluate the new formula, the authors
compared FFMDExA and FFMForm with different formulas in
various age categories. In male but not in female COPD
patients, FFMDExA decreased with increasing age. These
findings are in line with findings in healthy elderly, were
FFM assessed by BIA decreased from 35 to 55 y in men but
remained stable in women.25 Another study reported that
the FFM decreased after 60 y in men, and to a lower extent
also in women.26 These data imply that, at least the
pattern, of the age-dependant progress remains compa-
rable in patients with COPD and healthy subjects. Moreover
as expected, the new formula was closely linked to the
FFMDExA, as did the formula by Dey et al.
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Limitations of the study
The authors would like to address various limitation of the
study. Firstly, the DEXA scan was used as the reference
method for the FFM. The authors are aware that the DEXA
scan is not the golden standard for body compositional
measurement, like double labeled water technique or
magnetic resonance imaging.27 There are few studies
determining the accuracy of the DEXA scan for muscle mass
assessment. These studies concluded that DEXA scan
showed better precision compared to bedside methods like
BIA.28 Indeed, DEXA has been shown as a useful technique
to measure FFM in patients with COPD.8 Furthermore,
FFMDExA was assessed by summing up lean mass and bone
mineral content. It has been shown that bone mineral
content is lower in patients with COPD compared to healthy
controls,29 which could contribute to the lower FFMDExA
compared to the FFMBIA. Nevertheless, the contribution of
the bone mineral content to the FFM is relatively small and
is therefore unlikely to influence our results. Secondly,
patients with clinically diagnosed edema were excluded
from the study, but it cannot be concluded that all patients
were free of any level of edema. Especially in patients with
Assessment of muscle wasting in COPD 97extreme low FFM, the extracellular water compartment can
be increased.4 In these patients with non-visual levels of
edema, the body composition data are not reliable. This
hassle counts for both the BIA and the DEXA technique.
To summarize, the results of the present study show that
both the technique to determine FFM and the cut-offs to
define an abnormal low FFMI are of importance to accu-
rately diagnose muscle wasting in patients with COPD. The
authors concluded that the formula derived in the present
study can be used for the FFM assessment by using BIA in
clinically stable patients with COPD.
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